Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial

BACKGROUND: Combination irinotecan and cetuximab is approved for irinotecan-refractory metastatic colorectal cancer (mCRC). It is unknown if adding bevacizumab improves outcomes. PATIENTS AND METHODS: In this multicenter, randomized, double-blind, placebo-controlled phase II trial, patients with iri...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipsyc-Sharf, Marla, Ou, Fang-Shu, Yurgelun, Matthew B, Rubinson, Douglas A, Schrag, Deborah, Dakhil, Shaker R, Stella, Philip J, Weckstein, Douglas J, Wender, Donald B, Faggen, Meredith, Zemla, Tyler J, Heying, Erica N, Schuetz, Samantha R, Noble, Stephanie, Meyerhardt, Jeffrey A, Bekaii-Saab, Tanios, Fuchs, Charles S, Ng, Kimmie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Gastrointestinal Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982431/
https://www.ncbi.nlm.nih.gov/pubmed/35380713
http://dx.doi.org/10.1093/oncolo/oyab025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982431/
https://www.ncbi.nlm.nih.gov/pubmed/35380713
http://dx.doi.org/10.1093/oncolo/oyab025

Ejemplares similares